CRF unveils late-breaking clinical trials for TCT 2025 in San Francisco
The Cardiovascular Research Foundation (CRF) has released its full lineup of late-breaking clinical trials and late-breaking clinical science for Transcatheter Cardiovascular Therapeutics (TCT) 2025 in San Francisco. Topics to be featured during these sessions include percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), intravascular lithotripsy, valvular heart disease and much more.
This year marks the 37th annual meeting of the TCT conference. Interventional cardiologist Martin B. Leon, MD, a professor of medicine at Columbia University Irving Medical Center in New York and CRF’s founder, first started TCT back in 1988. Since then, it has grown into one of interventional cardiologist’s biggest events, bringing in specialists from all over the world.
TCT 2025 is scheduled for Oct. 25-28, 2025, at the Moscone Center in San Francisco.
Read on for the full schedule of late-breaking clinical trials and clinical science:
Late-Breaking Clinical Trials: Session 1
Sunday, Oct. 26 | 11 a.m. | Main Arena | Hall A
• One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesion. Presented by: Christian M. Spaulding, MD, PhD.
• Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis. Presented by: Donald Cutlip, MD.
• Randomized Comparison of Intravascular Lithotripsy vs. Cutting Balloon Treatment in Calcified Coronary Artery Disease – The Short-CUT Trial. Presented by: Suzanne J. Baron, MD, MSc.
• A Randomized, Multicenter, Non-Inferiority Comparison of Intravascular Lithotripsy and Super-High-Pressure Non-Compliant Balloons for Treatment of Calcified and Refractory Coronary Lesions - The VICTORY Trial. Presented by: Jeffrey W. Moses, MD.
Late-Breaking Clinical Trials: Session II
Monday, Oct. 27 | 11 a.m. | Main Arena | Hall A
• Defining the Prevalence of Valvular Heart Disease in Older Americans: The PREVUE-VALVE Study. Presented by: David J. Cohen, MD.
• Long-Term Follow-up of the PARTNER 3 Low-Risk Randomized Trial: Seven-Year Clinical and Echocardiographic Outcomes. Presented by: Michael J. Mack, MD.
• Tendyne Transcatheter Mitral Valve System in Patients with Severe Mitral Annular Calcification: One-year Outcomes from the SUMMIT Severe MAC Cohort. Presented by: Paul Sorajja, MD.
• Percutaneous Transseptal Transcatheter Mitral Valve Replacement using a Dedicated Balloon Expandable • Valve: 1 Year Outcomes from the ENCIRCLE Trial using the Sapien M3. Presented by: David Daniels, MD.
Late-Breaking Clinical Trials: Session III
Tuesday, Oct. 28 | 11 a.m. | Main Arena | Hall A
• Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR): A Multicenter, Open-label, Randomized Trial. Presented by: Ruben de Winter, MD.
• Effects of Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator as an Ajunct to Primary PCI in Patients with STEMI and Large Thrombus Burden: A Randomized, Double-Blind, Placebo-Controlled Trial. Presented by: Shamir R. Mehta, MD.
• Immediate Instantaneous Wave-Free Ratio Guided Versus Deferred Cardiac Magnetic Resonance Imaging Guided Revascularization of Non-Culprit Lesions in Patients with Acute ST-Elevation Myocardial Infarction: A Randomized Superiority Trial. Presented by: Robin Nijveldt, PhD, MD.
• Stratified Treatment of Myocardial Infarction with Non-Obstructive Coronary Arteries: The PROMISE Trial. Presented by: Rocco Antonio Montone, MD, PhD.
• Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial. Presented by: Upendra Kaul, MD.
Philippe Généreux, MD, presenting EARLY TAVR data at TCT 2024.
Late-Breaking Clinical Science: Session I
Sunday, Oct. 26 | 2 p.m. | Moscone Center
• Randomized Controlled Trial of Mechanical Thrombectomy with Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Results from STORM-PE. Presented by: Robert A. Lookstein, MD.
• Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions. Presented by: Sahil A. Parikh, MD.
• Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. Presented by: Josep Rodés-Cabau, MD, PhD.
• Evaluating Real-World Outcomes of the Evoque Valve in Early Commercial Experience from the STS/ACC TVT Registry. Presented by: Raj Makkar, MD.
• Lessons Learned from 800+ Patients Treated with Tricuspid TEER: Update from the TRILUMINATE Pivotal Trial. Presented by: Jonathan G. Schwartz, MD.
Late-Breaking Clinical Science: Session II
Monday, Oct. 27 | 2 p.m. | Moscone Center
• Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial. Presented by: David Erlinge, MD, PhD.
• Comparison of Drug-Coated Versus Conventional Balloons for Treatment of Side Branches of Bifurcation Lesions: The OCVC-BIF Study. Presented by: Takayuki Ishihara, MD.
• Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial. Presented by: Lei Song, MD.
• Drug-Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of DeNovo Coronary Artery Lesions: 3-Year Clinical Outcomes of the REC-CAGEFREE I Trial. Presented by: Chao Gao, MD, PhD.
• Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: 10-year Mortality Outcomes from the Randomized NOBLE Trial. Presented by: Evald H. Christiansen, MD, PhD.
Late-Breaking Clinical Science: Session III
Tuesday, Oct. 28 | 2 p.m. | Main Arena | Hall A
• iFR Versus Angiography-Guided CABG: 3-Year Results of the iCABG Randomized Trial. Presented by: Rasa Ordiene, MD.
• Randomized Comparison of the Supraflex Cruz vs. Synergy Drug-Eluting Stents: The Multivessel TALENT Randomized Trial. Presented by: Patrick W. Serruys, MD, PhD.
• A Prospective, Randomized Clinical Trial of Hemodynamic Support with a Novel Developed pVAD Versus IABP in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Presented by: Rui Wang, MD.
• AI-Enabled ECG Interpretation in STEMI: Findings from a Multicenter U.S. Registry. Presented by: Timothy D. Henry, MD.
• The Effectiveness and Safety of a Planned Investment Procedure in High-Risk Chronic Total Occlusions - The INVEST CTO Single Arm Study. Presented by: Anja Oksnes, MD.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.